Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.

News Market Reaction – ARMP

-11.61%

1 alert

-11.61% News Effect

On the day this news was published, ARMP declined 11.61%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19^th in Boston, MA.

For more information: https://phagefuturesusa.com/events/phage-futures-2024

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-5th-annual-phage-futures-annual-meeting-302309391.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Dr. Deborah Birx presenting at the Phage Futures Annual Meeting for ARMP?

Dr. Deborah Birx is presenting at 1:15pm ET on November 19th, 2024, at the 5th Annual Phage Futures Annual Meeting in Boston, MA.

What is Armata Pharmaceuticals (ARMP) main focus?

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Where is the 5th Annual Phage Futures Meeting for ARMP being held?

The 5th Annual Phage Futures Meeting is being held in Boston, MA.